This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00317408
First received: April 19, 2006
Last updated: September 24, 2015
Last verified: September 2015
  Purpose

RATIONALE: Giving combination chemotherapy and total-body irradiation before a peripheral stem cell transplant that uses the patient's or a donor's stem cells, helps stop both the growth of cancer cells and the patient's immune system from rejecting the stem cells. When the stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving combination chemotherapy and total-body irradiation followed by a stem cell transplant may be an effective treatment for anaplastic large cell lymphoma.

PURPOSE: This clinical trial is studying how well combination chemotherapy followed by stem cell transplant works in treating young patients with progressive or relapsed anaplastic large cell lymphoma.


Condition Intervention
Lymphoma Biological: anti-thymocyte globulin Drug: busulfan Drug: carboplatin Drug: carmustine Drug: cyclosporine Drug: cytarabine Drug: dexamethasone Drug: etoposide phosphate Drug: idarubicin Drug: ifosfamide Drug: leucovorin calcium Drug: lomustine Drug: melphalan Drug: methotrexate Drug: mitoxantrone hydrochloride Drug: prednisolone Drug: thiotepa Drug: vinblastine sulfate Drug: vindesine Procedure: allogeneic hematopoietic stem cell transplantation Procedure: autologous hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation Radiation: total-body irradiation

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Event-free survival as measured by the Kaplan-Meier method

Secondary Outcome Measures:
  • Proportion of patients who are treated on protocol among all patients who meet the inclusion criteria
  • Overall survival
  • Acute and long term toxicity
  • Rate of acute and chronic graft-vs-host disease in patients with allogeneic stem cell transplantation
  • Treatment related mortality

Estimated Enrollment: 96
Study Start Date: April 2004
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed anaplastic large cell lymphoma (ALCL)

    • Progressive disease OR first relapse
    • No second or subsequent relapse of ALCL
  • Slides available for national central pathology review
  • Availability of 1 of the following (for allogeneic stem cell transplantation only):

    • HLA-identical matched sibling donor
    • 10/10 HLA-matched nonsibling donor (related or unrelated)
    • 9/10 HLA-matched nonsibling donor (1-antigen-mismatched related or unrelated donor)
    • < 9/10 HLA-mismatched donor (related or unrelated)

      • Stem cells may be obtained from unmanipulated bone marrow or peripheral blood stem cells after filgrastim (G-CSF) stimulation

PATIENT CHARACTERISTICS:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Adequate hepatic, renal, and cardiac function
  • No HIV infection or AIDS
  • No severe immunodeficiency
  • No other prior malignancy
  • No pre-existing disease or condition prohibiting study treatment

PRIOR CONCURRENT THERAPY:

  • At least 2 months since prior chemotherapy or radiotherapy
  • No significant pretreatment for first relapse
  • No prior organ transplantation
  • No concurrent participation in another clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00317408

  Show 98 Study Locations
Sponsors and Collaborators
European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma
Investigators
Study Chair: Alfred Reiter, MD University Hospital Erlangen
OverallOfficial: Denise Williams, MD Cambridge University Hospitals NHS Foundation Trust
  More Information

ClinicalTrials.gov Identifier: NCT00317408     History of Changes
Other Study ID Numbers: CDR0000466639
EICNHL-ALCL-RELAPSE
AIEOP-EICNHL-ALCL-RELAPSE
BFM-EICNHL-ALCL-RELAPSE
BSPHO-EICNHL-ALCL-RELAPSE
DCOG-EICNHL-ALCL-RELAPSE
NOPHO-EICNHL-ALCL-RELAPSE
PPLLSG-EICNHL-ALCL-RELAPSE
SFCE-EICNHL-ALCL-RELAPSE
SHOP-EICNHL-ALCL-RELAPSE
CCLG-NHL-2006-01
EU-205118
EU-20618
EUDRACT-2005-003321-57
Study First Received: April 19, 2006
Last Updated: September 24, 2015

Keywords provided by National Cancer Institute (NCI):
anaplastic large cell lymphoma
recurrent childhood anaplastic large cell lymphoma
stage III childhood anaplastic large cell lymphoma
stage IV childhood anaplastic large cell lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, Large-Cell, Anaplastic
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, T-Cell
Dexamethasone
Prednisolone
Etoposide phosphate
Carboplatin
Methotrexate
Etoposide
Cytarabine
Melphalan
Busulfan
Ifosfamide
Mitoxantrone
Idarubicin
Thiotepa
Vinblastine
Carmustine
Lomustine
Vindesine
Cyclosporine
Cyclosporins
Antilymphocyte Serum

ClinicalTrials.gov processed this record on July 19, 2017